Death receptors in chemotherapy and cancer

被引:400
作者
Debatin, KM
Krammer, PH
机构
[1] Univ Childrens Hosp, D-89075 Ulm, Germany
[2] German Canc Res Ctr, D-69120 Heidelberg, Germany
关键词
apoptosis; death receptors; CD95; drugs; resistance;
D O I
10.1038/sj.onc.1207558
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apoptosis, the cell's intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies such as chemotherapy, gamma-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target cells. In addition to the intrinsic mitochondrial pathway, elements of death receptor signaling pathways have been implied to contribute to the efficacy of cancer therapy. Failure to undergo apoptosis in response to anticancer therapy may lead to resistance. Also, deregulated expression of death receptor pathway molecules may contribute to tumorigenesis and tumor escape from endogenous growth control. Understanding the molecular events that regulate apoptosis induced by anticancer therapy and how cancer cells evade apoptosis may provide new opportunities for pathway-based rational therapy and for drug development.
引用
收藏
页码:2950 / 2966
页数:17
相关论文
共 288 条
  • [1] Expression and prognostic significance of survivin in de novo acute myeloid leukaemia
    Adida, C
    Recher, C
    Raffoux, E
    Daniel, MT
    Taksin, AL
    Rousselot, P
    Sigaux, F
    Degos, L
    Altieri, DC
    Dombret, H
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 196 - 203
  • [2] Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
    Adida, C
    Berrebi, D
    Peuchmaur, M
    Reyes-Mugica, M
    Altieri, DC
    [J]. LANCET, 1998, 351 (9106) : 882 - 883
  • [3] The mitochondrial apoptosome: a killer unleashed by the cytochrome seas
    Adrain, C
    Martin, SJ
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (06) : 390 - 397
  • [4] Two CD95 tumor classes with different sensitivities to antitumor drugs
    Algeciras-Schimnich, A
    Pietras, EM
    Barnhart, BC
    Legembre, P
    Vijayan, S
    Holbeck, SL
    Peter, ME
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) : 11445 - 11450
  • [5] Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
    Allison, J
    Georgiou, HM
    Strasser, A
    Vaux, DL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3943 - 3947
  • [6] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [7] The molecular basis and potential role of survivin in cancer diagnosis and therapy
    Altieri, DC
    [J]. TRENDS IN MOLECULAR MEDICINE, 2001, 7 (12) : 542 - 547
  • [8] Survivin and apoptosis control
    Altieri, DC
    [J]. ADVANCES IN CANCER RESEARCH, VOL 88, 2003, 88 : 31 - 52
  • [9] Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer
    Apolinario, RM
    vanderValk, P
    deJong, JS
    Deville, W
    vanArkOtte, J
    Dingemans, AMC
    vanMourik, JC
    Postmus, PE
    Pinedo, HM
    Giaccone, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2456 - 2466
  • [10] Gene transfer of Fas ligand induces tumor regression in vivo
    Arai, H
    Gordon, D
    Nabel, EG
    Nabel, GJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) : 13862 - 13867